微信公众号

官网二维码
中国癌症防治杂志

中国癌症防治杂志 ›› 2025, Vol. 17 ›› Issue (4): 452-457.doi: 10.3969/j.issn.1674-5671.2025.04.09

• 论著 • 上一篇    下一篇

肿瘤患者经中心静脉输注优替德隆发生导管相关皮肤不良反应的现状及其影响因素分析

  

  1. 中山大学肿瘤防治中心内科
  • 出版日期:2025-08-25 发布日期:2025-09-12
  • 通讯作者: 石思梅 E-mail：shism@sysucc.org.cn

Analysis of the present status of catheter⁃related dermatological adverse reactions in cancer patients undergoing central venous infusion of Utidelone and its influencing factors

  • Online:2025-08-25 Published:2025-09-12

PDF (PC)

561

赞

摘要： 目的 探讨经中心静脉输注优替德隆的肿瘤患者导管相关皮肤不良反应的发生率及影响因素。方法 回顾性分析2021年3月至2024年3月在中山大学肿瘤防治中心应用经外周静脉置入的中心静脉导管（peripherally inserted central catheter,PICC）或完全植入式输液港（totally implanted access port,TIAP）输注优替德隆的肿瘤患者的临床资料。采用单因素分析和二分类Logistic回归分析其发生导管相关皮肤不良反应的影响因素。结果  在纳入研究的205例患者中， 40（19.5%）例发生导管相关皮肤不良反应，其中29（72.5%）例导致输液装置非计划拔除。单因素分析结果显示，导管相关皮肤不良反应的发生与饮酒史、优替德隆总疗程、输注方式、导管类型及置管静脉等因素显著相关（均P<0.05）；进一步Logistic回归分析结果显示，有饮酒史（OR=8.112，95%CI=1.616~40.728）、优替德隆总疗程数越多（OR=1.212，95%CI=1.043~1.409）、置管静脉为颈内静脉（TIAP，OR=4.816，95%CI=1.136~20.425）或肱静脉（PICC，OR=34.171，95%CI=2.136~546.573）是导管相关皮肤不良反应的危险因素。结论 在经中心静脉输注优替德隆的患者中，导管相关皮肤不良反应的发生率相对较高，可能与饮酒史、治疗总疗程以及置管静脉选择有关。建议医护人员加强对导管周围皮肤的监测，并制定针对这些影响因素的预防措施，以减少不良反应的发生率。

关键词: 肿瘤, 中心静脉, 优替德隆, 导管相关皮肤不良反应, 影响因素

Abstract: Objective To investigate the incidence of catheter⁃related dermatological adverse reactions in cancer patients undergoing central venous infusion of Utidelone and the influencing factors. Methods A retrospective analysis was conducted on clinical data from cancer patients who received Utidelone infusions via peripherally inserted central catheter (PICC) or totally implanted access port (TIAP) at Sun Yat⁃sen University Cancer Center between March 2021 and March 2024. To investigate the factors influencing cathete⁃related dermatological adverse reactions, univariable analysis and binary Logistic regression were employed. Results Among the 205 patients included in study, 40 (19.5%) experienced catheter⁃related dermatological adverse reactions, 29 (72.5%) of these cases resulting in the unplanned removal of the infusion device. Univariable analysis identified a significant association between the occurrence of catheter⁃related dermatological adverse reactions and factors such as alcohol consumption history, total cycles of Utidelone treatment, infusion method, type of catheter, and catheter insertion vein(all P<0.05). Further Logistic regression analysis identified several risk factors for catheter⁃related dermatological adverse reactions, including the alcohol consumption history (OR=8.112, 95%CI: 1.616-40.728), the more total cycles of Utidelone treatment (OR=1.212, 95%CI: 1.043-1.409), and catheter insertion via the internal jugular vein for TIAP (OR=4.816, 95%CI: 1.136-20.425) or brachial vein for PICC (OR=34.171, 95%CI: 2.136-546.573). Conclusions The incidence of catheter⁃related dermatological adverse reactions is relatively high in patients receiving Utidelone via central venous infusion, potentially influenced by alcohol consumption history, the total cycles of treatment, and the choice of insertion vein. It is recommended that healthcare providers enhance monitoring of skin around the catheter site and develop preventive strategies targeting these influencing factors to reduce the incidence of adverse reactions.

Key words: Cancer, Central venous, Utidelone, Catheter?related dermatological adverse reactions, Influencing factors

中图分类号: 

  • R730